Hexarelin vs Ipamorelin

Overview

Hexarelin and ipamorelin are both synthetic growth hormone releasing peptides (GHRPs) that stimulate GH secretion from the pituitary gland. Neither is FDA-approved for any indication, and both are sold as research chemicals.

Important: Both compounds are unapproved research peptides. Quality, purity, and safety cannot be guaranteed for products sold online.

Key Facts

Aspect	Hexarelin	Ipamorelin
Class	Growth hormone releasing peptide	Growth hormone releasing peptide
Structure	Hexapeptide (6 amino acids)	Pentapeptide (5 amino acids)
FDA Status	Not approved	Not approved
WADA Status	Prohibited (S2)	Prohibited (S2)
Administration	Subcutaneous injection	Subcutaneous injection

Mechanism Comparison

Aspect	Hexarelin	Ipamorelin
Primary Target	GHS-R1a (ghrelin receptor)	GHS-R1a (ghrelin receptor)
GH Release Potency	Higher	Moderate
Selectivity	Lower (affects cortisol, prolactin)	Higher (minimal cortisol/prolactin)
Desensitization	More pronounced	Less pronounced
Half-life	~2 hours	~2 hours

How They Work

Hexarelin:

• Binds to ghrelin receptor (GHS-R1a) in pituitary
• Produces robust GH release
• Also affects cortisol and prolactin levels
• May have some cardiac effects independent of GH
• More potent but less selective

Ipamorelin:

• Selective ghrelin receptor agonist
• Stimulates GH release with minimal effect on other hormones
• Does not significantly increase cortisol or prolactin
• Claimed to be “cleanest” GHRP
• May have less desensitization over time

Evidence Quality

Hexarelin Research

Trial Type	Status	Key Findings
GH release studies	Completed	Potent GH stimulation
Cardiac studies	Some completed	Potential cardiac effects
Long-term efficacy	Not established	—
FDA development	Not pursued	Development discontinued

Published research:

• More extensively studied than ipamorelin
• Cardiac effects investigated (mixed results)
• GH release well-documented
• Development did not proceed to approval

Ipamorelin Research

Trial Type	Status	Key Findings
GH release studies	Completed	GH stimulation confirmed
Selectivity studies	Limited	Less cortisol/prolactin effect
Gut motility	Some studies	Potential post-operative use
Clinical development	Limited	No major approval programs

Published research:

• Fewer published studies than hexarelin
• Selectivity profile documented
• Some interest in post-operative ileus
• No completed Phase 3 programs

Evidence Strength Comparison

Factor	Hexarelin	Ipamorelin
Peer-reviewed studies	More extensive	Limited
Human GH release data	Yes	Yes
Selectivity documentation	Moderate	Some
Long-term safety data	None	None
Overall quality	Low	Low

GH Release Comparison

Parameter	Hexarelin	Ipamorelin
Peak GH elevation	Higher	Moderate
Duration of effect	Similar	Similar
Dose-response	Steep	More gradual
Ceiling effect	Yes	Yes

Desensitization

Hexarelin:

• More prone to receptor desensitization
• GH response may diminish with continuous use
• May require cycling or breaks
• Higher initial response, less sustainable

Ipamorelin:

• Claims of less desensitization
• May maintain GH response better over time
• Limited long-term data to confirm
• Preferred for longer-term use (theoretical)

Side Effects

Hexarelin

Side Effect	Frequency	Mechanism
Cortisol elevation	Documented	Non-selective receptor activity
Prolactin elevation	Documented	Non-selective effects
Water retention	Reported	GH-related
Increased appetite	Common	Ghrelin pathway
Potential cardiac effects	Uncertain	Independent of GH (research)

Ipamorelin

Side Effect	Frequency	Mechanism
Injection site reactions	Occasional	Administration route
Headache	Reported	GH release
Flushing	Reported	—
Water retention	Possible	GH-related (mild)
Minimal hunger increase	Claimed	More selective

Key Safety Differences

Hexarelin disadvantages:

• Elevates cortisol (stress hormone)
• Elevates prolactin (can affect hormonal balance)
• More pronounced systemic effects
• Greater desensitization risk

Ipamorelin advantages (claimed):

• Minimal cortisol effect
• Minimal prolactin effect
• More selective GH release
• Potentially safer long-term profile

Comparison Table: Selectivity

Hormone Affected	Hexarelin	Ipamorelin
Growth Hormone	+++ (strong increase)	++ (moderate increase)
Cortisol	+ (increases)	+/- (minimal effect)
Prolactin	+ (increases)	+/- (minimal effect)
ACTH	+ (may increase)	- (minimal effect)
Ghrelin-like hunger	++	+

Practical Comparison

Factor	Hexarelin	Ipamorelin
GH release strength	Stronger	Moderate
Selectivity	Lower	Higher
Side effect profile	More concerns	Fewer concerns (claimed)
Long-term viability	Desensitization issue	May be more sustainable
Source availability	Research chemical	Research chemical
Quality assurance	None	None

Why Neither Is Approved

Factor	Both Compounds
Regulatory status	Research chemicals only
Clinical development	Not pursued to completion
Evidence base	Insufficient for approval
Safety data	Inadequate long-term data
Indication	No defined approved use

Claimed Uses (Unapproved)

Both peptides are marketed in the research community for:

• Increasing growth hormone levels
• Muscle growth and recovery
• Fat loss
• Anti-aging effects
• Sleep improvement

Evidence for claims: Limited to GH release demonstration. Functional outcomes (muscle, fat loss, aging) not established in controlled trials.

Who Uses Each (Research Context)

Hexarelin typically chosen by:

• Those wanting stronger initial GH release
• Short-term research protocols
• Those accepting cortisol/prolactin effects

Ipamorelin typically chosen by:

• Those prioritizing selectivity
• Longer-term research protocols
• Those avoiding cortisol/prolactin elevation
• Often combined with GHRH analogs (CJC-1295)

Summary

Factor	Hexarelin	Ipamorelin
GH release potency	Higher	Moderate
Selectivity	Lower	Higher
Cortisol effect	Increases	Minimal
Prolactin effect	Increases	Minimal
Desensitization	More prone	Less prone
Evidence quality	Low	Low
Approval status	Not approved	Not approved

Both hexarelin and ipamorelin are unapproved research peptides. Ipamorelin’s selectivity profile makes it theoretically preferable for those concerned about cortisol and prolactin effects, while hexarelin produces stronger initial GH release. Neither has adequate safety data for human use outside of research settings.

---

This comparison is for educational purposes only. Neither compound is FDA-approved. Consult a healthcare provider before considering any research compounds.